Why All the ImClone Interest? Its Pipeline
ImClone Systems (IMCL) is finally escaping its scandal-plagued past to become biotech's most desirable property, at least for the moment. That may seem odd, given that its sole product on the market—the cancer drug Erbitux—has not lived up to initial expectations. But industry experts say takeover interest from Eli Lilly (LLY), which on Oct. 6 said it will pay $6.5 billion in cash, is ImClone's future, not its past.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.